204 related articles for article (PubMed ID: 24136301)
1. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies.
Rajpal RK; Fong R; Comstock TL
Adv Ther; 2013 Oct; 30(10):907-23. PubMed ID: 24136301
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
Rajpal RK; Roel L; Siou-Mermet R; Erb T
J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
[TBL] [Abstract][Full Text] [Related]
3. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery.
Fong R; Silverstein BE; Peace JH; Williams JI; Vittitow JL
J Cataract Refract Surg; 2018 Oct; 44(10):1220-1229. PubMed ID: 30193927
[TBL] [Abstract][Full Text] [Related]
4. Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies.
Fong R; Cavet ME; DeCory HH; Vittitow JL
Clin Ophthalmol; 2019; 13():1427-1438. PubMed ID: 31447544
[TBL] [Abstract][Full Text] [Related]
5. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
[TBL] [Abstract][Full Text] [Related]
6. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial.
Fong R; Leitritz M; Siou-Mermet R; Erb T
Clin Ophthalmol; 2012; 6():1113-24. PubMed ID: 22888209
[TBL] [Abstract][Full Text] [Related]
7. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
Lane SS; Holland EJ
J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery.
Comstock TL; Paterno MR; Singh A; Erb T; Davis E
Clin Ophthalmol; 2011; 5():177-86. PubMed ID: 21383946
[TBL] [Abstract][Full Text] [Related]
9. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
Stewart R; Horwitz B; Howes J; Novack GD; Hart K
J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.
Henderson BA; Gayton JL; Chandler SP; Gow JA; Klier SM; McNamara TR;
Ophthalmology; 2011 Nov; 118(11):2120-7. PubMed ID: 21762992
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
[TBL] [Abstract][Full Text] [Related]
13. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
[TBL] [Abstract][Full Text] [Related]
14. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
Kang C; Keam SJ; Shirley M; Syed YY
Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521
[TBL] [Abstract][Full Text] [Related]
15. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
Abelson M; Howes J; George M
J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial.
Colin J; Paquette B
Clin Ther; 2006 Apr; 28(4):527-36. PubMed ID: 16750464
[TBL] [Abstract][Full Text] [Related]
17. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
[TBL] [Abstract][Full Text] [Related]
18. Loteprednol etabonate gel 0.5% vs prednisolone acetate suspension 1% for the treatment of inflammation after cataract surgery in children.
Vittitow JL; Williams JI
J Cataract Refract Surg; 2020 Aug; 46(8):1092-1101. PubMed ID: 32352250
[TBL] [Abstract][Full Text] [Related]
19. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
Donnenfeld ED; Holland EJ; Stewart RH; Gow JA; Grillone LR;
Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
[TBL] [Abstract][Full Text] [Related]
20. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
Asbell P; Howes J
CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
